Crohn’s disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised
by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a
substantial number of patients still require surgery for medically refractory disease or disease-related
complications. Given the widespread adoption of biologic therapies for the management of patients
with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at the time
of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While
more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab,
an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on
the postoperative outcomes for CD patients exposed to ustekinumab perioperatively.
Keywords: Ustekinumab, Crohn's disease, surgery, chronic inflammatory, biologic therapies, vedolizumab.
Gionchetti P, Dignass A, Danese S, et al. ECCO Guidelines/Consensus Paper 3rd European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohn’s Colitis 2017; 11(2): 135-49.
Rights & PermissionsPrintExport